PepGen Stock Falls 13% on the Day After It Filed for a $125 Million Share Sale
The company agreed to sell 25 million shares at $5.00 each, and the filings do not say why the stock fell that day.

Key points
- PepGen shares fell 13.5% Friday, the session after it filed for a $125 million stock offering
- The company agreed to sell 25 million shares at $5.00 each; the underwriters have a 30-day option for 3.75 million more
- Net proceeds are expected to be about $116.9 million
- Cash and investments together were $104.8 million at Sept. 30, 2026
PepGen Inc. (Nasdaq: PEPG) shares fell 13.5% on Friday, Nov. 13, 2026, the session after the clinical-stage biotechnology company filed papers for a public stock offering. The stock closed at $4.36, down from $5.04 the previous session, on volume about five times its usual level. The S&P 500 ETF (SPY) fell 0.36% over the same session. Neither the filings nor the company's press releases state why the shares fell that day.
Offering priced at $5.00 a share
The company agreed to sell 25,000,000 shares of common stock at $5.00 each, according to an 8-K filed Nov. 12, 2026. A prospectus supplement filed the same afternoon described the offering. Gross proceeds total $125 million before underwriting discounts and commissions. The underwriters have a 30-day option to buy up to 3,750,000 more shares.
Proceeds and cash position
After discounts and estimated expenses, PepGen expects net proceeds of about $116.9 million, or about $134.5 million if the option is exercised in full. The company said it intends to use the money to fund clinical development of its product candidate, PGN-EDODM1, along with working capital and other general corporate purposes.
As of Sept. 30, 2026, cash, equivalents and short-term investments together totaled $104.8 million. The company's net loss for the third quarter of 2026 was $19.4 million. The offering would lift shares outstanding to about 94.3 million from 69.3 million at Sept. 30.
Sources
Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.
Other stock movers this week
- Woodward Stock Rises 5% After Record Fiscal 2026 Results and Strong Fourth Quarter · WWD · Nov. 19, 2026
- J&J Snack Foods Stock Jumps 9.5% on Fiscal Q4 Results and Cost Savings Update · JJSF · Nov. 18, 2026
- Valvoline Stock Rises 10% as Fourth-Quarter Results Are Released · VVV · Nov. 19, 2026
- ACI Worldwide Stock Falls 10% as CEO Thomas Warsop Resigns and CFO Takes Interim Role · ACIW · Nov. 18, 2026
More on PepGen
PEPG page →
PepGen Stock Soars 93% on Positive Data From Phase 2 Myotonic Dystrophy Trial
The biotech reported 46.5% mean splicing correction at the 10 mg/kg dose alongside its third-quarter results, with no serious adverse events reported.